C4 Therapeutics (CCCC) AI Stock Analysis

• Market Cap: $92.29M
• Dividend Yield: N/A
• Average Volume (3M): 976.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.88
• Revenue Growth: 71.44%
• EPS Growth: 43.22%
• Country: US
• Employees: 110
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -1.51
• Shares Outstanding: 70,989,660
• 10 Day Avg. Volume: 943,801
• 30 Day Avg. Volume: 976,393
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 4.23
• Price to Cash Flow (P/CF): -2.10
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $11.88
• Price Target Upside: 813.85% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

C4 Therapeutics faces significant financial challenges, with issues in profitability and liquidity. The technical indicators suggest downward pressure on the stock price, and valuation metrics are not favorable. However, recent corporate events indicate strategic progress and potential for future growth. Overall, the stock score reflects these mixed signals, primarily weighted by financial and technical concerns.

Positive Factors

Partnership opportunity

Management intends to partner cemsi to maximize value, which could result in a rally of shares upon an announcement.

Product potential

CFT1946 has the potential to replace BRAF inhibitors and be CCCC's first wholly-owned commercial product.

Valuation and growth

The company's valuation at an EV of ~$50MM suggests a significant opportunity for growth, as the market currently assigns no value to certain promising programs.

Negative Factors

Adverse events

There were notable Grade 3 or higher treatment-related adverse events, such as neutropenia and anemia.

Unannounced partnership

CCCC has expressed its intent to partner the cemsidomide program, but a partnership has not yet been announced.

C4 Therapeutics Business Overview & Revenue Model

Company Description

C4 Therapeutics, Inc. (CCCC) is a biotechnology company focused on developing novel therapies for the treatment of cancer and other diseases. The company leverages its proprietary Degronimids platform to create targeted protein degraders that aim to selectively and efficiently eliminate disease-causing proteins. C4 Therapeutics operates primarily in the biotechnology and pharmaceutical sectors, with a core focus on advancing its pipeline of drug candidates through preclinical and clinical development stages.

How the Company Makes Money

C4 Therapeutics makes money primarily through collaboration agreements with larger pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific research, development, or regulatory milestones, and potential royalties on future product sales. The company may also generate revenue by advancing its proprietary drug candidates through clinical trials, ultimately aiming to bring them to market. Key revenue streams include milestone payments from existing collaborations and prospective revenue from future commercialization of its drug candidates.

C4 Therapeutics Financial Statement Overview

Summary

C4 Therapeutics has shown revenue growth but faces significant profitability challenges. The balance sheet is stable with a solid equity position, yet negative returns highlight operational inefficiencies. Continued reliance on external financing for cash flow support suggests liquidity concerns.

Income Statement

C4 Therapeutics has experienced fluctuating revenue growth with a notable increase of 71.37% in TTM compared to the previous year. However, profitability remains a concern with negative net and EBIT margins. The gross profit margin improved significantly in the TTM period, but overall, the company struggles with operational inefficiencies reflected in persistent losses.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio of 0.30 in the TTM period, indicating manageable debt levels relative to equity. However, the equity ratio stands at 61.77%, reflecting a strong capital structure. The return on equity remains negative due to net losses, highlighting a need for improved profitability.

Cash Flow

C4 Therapeutics faces challenges with negative free cash flow growth and a high operating cash flow to net income ratio, mainly due to consistent operating losses. The reliance on financing activities to support cash flow is a concern, indicating potential liquidity risks.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
35.58M	20.76M	31.10M	45.78M	33.20M	21.38M
	Gross Profit
29.46M	-96.95M	23.52M	42.88M	-44.27M	-26.28M
	EBIT
-119.61M	-139.03M	-129.53M	-82.13M	-60.45M	-35.45M
	EBITDA
-98.58M	-122.10M	-124.28M	-78.84M	-62.89M	-30.56M
	Net Income Common Stockholders
-105.32M	-132.49M	-126.50M	-86.04M	-66.33M	-34.10M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
258.19M	253.68M	337.12M	309.28M	371.69M	90.55M
	Total Assets
398.37M	376.45M	430.84M	506.76M	400.14M	118.26M
	Total Debt
69.72M	70.98M	87.15M	42.88M	22.92M	13.75M
	Net Debt
-19.94M	-55.61M	57.40M	-33.24M	-158.81M	-76.80M
	Total Liabilities
140.09M	130.34M	141.61M	117.16M	119.35M	230.22M
	Stockholders Equity
258.28M	246.11M	289.23M	389.61M	280.79M	-111.96M
Cash Flow		Free Cash Flow
-65.34M	-108.55M	-111.44M	-88.24M	-67.90M	54.27M
	Operating Cash Flow
-65.16M	-106.84M	-105.94M	-86.97M	-67.25M	55.61M
	Investing Cash Flow
-51.27M	158.35M	58.42M	-189.34M	-190.50M	-1.62M
	Financing Cash Flow
45.34M	45.49M	1.15M	171.40M	348.93M	244.00K

C4 Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCCC, the sentiment is Negative. The current price of 1.3 is below the 20-day moving average (MA) of 1.78, below the 50-day MA of 2.48, and below the 200-day MA of 4.58, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 20.72 is Positive, neither overbought nor oversold. The STOCH value of 1.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCCC.

C4 Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GLUE	57 Neutral	$249.73M	―	-36.15%	―	―	61.09%
KYMR	50 Neutral	$1.56B	―	-36.38%	―	-40.11%	-17.79%
FHTX	48 Neutral	$196.87M	―	322.49%	―	-33.83%	27.89%
Sector *	48 Neutral	$6.36B	1.28	-45.04%	2.64%	19.24%	1.69%
NRIX	48 Neutral	$731.86M	―	-64.16%	―	-30.25%	-5.92%
ARVN	46 Neutral	$462.83M	―	-35.41%	―	-39.92%	7.38%
CCCC	43 Neutral	$92.29M	―	-45.58%	―	71.44%	43.22%

C4 Therapeutics Corporate Events

C4 Therapeutics Outlines 2025 Milestones and Achievements

On January 14, 2025, C4 Therapeutics announced its anticipated milestones for the year, highlighting continued progress in its clinical portfolio of degrader medicines targeting high unmet needs in oncology. The company showcased its achievements in 2024, including advancements in clinical trials for cemsidomide and CFT1946, with significant data expected in the second half of 2025. C4T also announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference and reported a strong cash position to support operations into 2027. These developments position C4T as a promising player in the biopharmaceutical industry, focusing on innovative treatments for oncology patients.